Хлорфенвинфос: Свойства, Применение и Опасность

Chlorfenvinphos is an organophosphorus compound that was widely used as an insecticide and an acaricide. The molecule itself can be described as an enol ester derived from dichloroacetophenone and diethylphosphonic acid. Chlorfenvinphos has been included in many products since its first use in 1963. However, because of its toxic effect as a cholinesterase inhibitor it has been banned in several countries, including the United States and the European Union. Its use in the United States was cancelled in 1991. The pure chemical is a colorless solid, but for commercial purposes, it is often marketed as an amber liquid. The insecticides, mostly used in liquid form, contain between 50% and 90% chlorfenvinphos. The substance easily mixes with acetone, ethanol, and propylene glycol. Furthermore, chlorfenvinphos is corrosive to metal and hydrolyzes in the environment. It is classified as an extremely hazardous substance in the United States as defined in Section 302 of the U. S. Emergency Planning and Community Right to Know Act (42 U. S. C. 11002), and is subject to strict reporting requirements by facilities which produce, store, or use it in significant quantities.

Dermaton was the first registered product containing chlorfenvinphos. It was introduced in the United States in 1963 and was used as an insecticide and acaricide for controlling fleas and ticks on domestic pets and other animals. Between 1963 and 1970, additional uses were registered, including the use as fly spray, surface spray and larvicide. Because of these effects, chlorfenvinphos was often used on farms to control adult flies in dairy barns, milk rooms, poultry houses and yards, and in other animal buildings. Furthermore, it was used to control larval flies in manure storage pits and piles and other refuse accumulation areas around dairies and feedlots. Outside the United States, chlorfenvinphos, registered under the trade names Birlane, C8949, CGA 26351, Sapecron, Steladone and Supona, was used as a soil insecticide for controlling root maggots, root worms and cutworms. Chlorfenvinphos was also used against Colorado beetles on potatoes and scale insects and mite eggs on citrus. Furthermore, the compound had the same uses as in the United States. There is no quantitative information on the total volume of chlorfenvinphos really used as a pesticide in the United States or elsewhere. Since all uses of the chemical in the United States were canceled in 1991, use is likely to have declined, although there are no data showing this trend.

No international regulations exist for the use of chlorfenvinphos, although standards and guidelines have been set to protect people from the possible harmful effects of the toxin. No regulation exists for inhalation exposure, but multiple minimal risk levels (MRL) have been estimated for oral exposure. These data have been developed from lowest observed adverse effect levels (LOAEL) in test rats, based on adverse neurological effects. The acute oral MRL has been established at 0.002 mg/kg/day, while the chronic MRL has been established somewhat lower, at 0.0007 mg/kg/day. Furthermore, chlorfenvinphos is one of the chemicals regulated under “The Emergency Planning and Community Right to Know act of 1986”. This means that owners and operators of certain facilities that manufacture, import, process or otherwise use the chemical, are obligated to report their annual release of the chemical to any environmental media.

Chlorfenvinphos was first introduced in the United States in 1963, by the Shell International Chemical Company Ltd., Ciba AG (now Ciba Geigy AG) and by Allied Chemical Corporation. Its main use was as an insecticide and acaricide used to control insect pests on livestock and household pests such as flies, fleas, and mites. Since its first application, many manufacturers included chlorfenvinphos in their products. Some common trade names are Birlane, Dermaton, Sapercon, Steladone, and Supona. Moreover, there have been no registered uses for this compound as a pesticide in the United States since 1995. Unfortunately, no data is available in the Toxics Release Inventory (TRI) database on total environment releases of this compound from facilities. This is mainly because chlorfenvinphos was not considered a dangerous toxin until the early 1990s. Therefore, chlorfenvinphos is not one of the compounds about which facilities were required to report to the Toxic Release Inventory. However, as an organophosphorus compound, it does not accumulate well in tissues. The first and most important step of metabolism of chlorfenvinphos in humans is accomplished by the enzyme cytochrome P450 in liver microsomes. This enzyme facilitates oxidative dealkylation of the compound to acetaldehyde and 2 chloro 1 (2,4 dichlorophenyl) vinylethylhydrogen phosphate, the latter of which quickly breaks down to acetophenone. Acetophenone is then reduced to an alcohol and conjugated by glutathione transferases.,

Excretion of chlorfenvinphos is fairly rapid. In rats, an administered dose is excreted in 4 days, mostly in urine.

The toxicity of chlorfenvinphos is primarily caused by its inhibition of cholinesterase activity. Chlorfenvinphos reacts with the acetylcholine binding sites of enzymes that hydrolyze acetylcholine, thereby preventing their catalysis of this reaction. The reaction itself is a phosphorylation, which is reversible. The phosphorylated enzymes can undergo conformational changes and additional reactions however, which prevent the dephosphorylation. This “aging” results in irreversible inhibition of the cholinesterase.

The acute toxicity of chlorfenvinphos varies widely between species. Oral LD50 values range from 9.6–39 mg/kg in rats to >12,000 mg/kg in dogs. Though no direct data on the acute toxicity in humans is available, an in vitro study of the detoxification of chlorfenvinphos has shown that human liver enzymes were almost as effective as those of rabbits, who have an oral LD50 of 412 4,700 mg/kg.,

Prolonged exposure to chlorfenvinphos has been observed to decrease plasma and erythrocyte cholinesterase activity in humans. No significant genotoxicity, carcinogenicity or teratogenicity has been reported. On the basis of a NOAEL of 0.05 mg/kg observed in rats, an acceptable daily intake for humans of 0.0005 mg/kg has been established.